# A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

Source: https://onco.cc/trials/nct05787613/  
OnCo record `nct05787613` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HLX26 and Serplulimab in non-small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.

## Summary

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients is a phase 2 interventional study registered as NCT05787613 by Shanghai Henlius Biotech, with 132 participants enrolled, started 2023-07-10 and due to reach its primary completion in 2026-02. Interventions recorded: HLX26, Serplulimab, Chemotherapy drug and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05787613
- Phase: 2
- Setting: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab (Anti-PD-1 Humanized Monoclonal Antibody Injection) and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) Patients
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 132

## Sources

- ClinicalTrials.gov NCT05787613: https://clinicaltrials.gov/study/NCT05787613

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [HLX26](https://onco.cc/drugs/hlx26/), [Serplulimab](https://onco.cc/drugs/serplulimab/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct05787613.json